|Bid||272.41 x 800|
|Ask||280.33 x 800|
|Day's Range||278.34 - 285.17|
|52 Week Range||209.00 - 296.67|
|Beta (5Y Monthly)||0.58|
|PE Ratio (TTM)||23.08|
|Forward Dividend & Yield||7.76 (2.98%)|
|Ex-Dividend Date||Aug 17, 2022|
|1y Target Est||N/A|
Mirati Therapeutics' (MRTX) preliminary data from the first-line NSCLC study showed that adagrasib plus Merck's Keytruda achieved an objective response rate of 49%.
When we invest, we're generally looking for stocks that outperform the market average. And the truth is, you can make...
Early trial data shows that a combination of Mirati Therapeutics experimental drug adagrasib and Merck & Co's immunotherapy Keytruda helped about half of previously untreated metastatic lung cancer patients, with manageable side effects, Mirati said on Monday. The company expects the largest advantage in patients with lower levels of PDL1, the protein targeted by Keytruda, and plans to launch a phase-three trial enrolling only those patients soon, Mirati chief executive officer David Meek told Reuters.